An updated analysis of the eNRGy trial showed that zenocutuzumab may provide meaningful benefit beyond initial disease progression.
Zhaohui Liao Arter, MD
Advertisement
Articles by Zhaohui Liao Arter, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Will The FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma?
2
FDA Grants Tentative Approval to PNT2003 for GEP-NETs
3
DURGA-1 Trial Shows Encouraging Results With Novel Multiple Myeloma Agent
4
What Were The Key Prostate Cancer Abstracts at ASCO GU 2026?
5